タバコたばこ使用者におけるアナバシン排泄因子の推定:予備的評価
Min-Tz Weng1, Qiuda Zheng2, Yao Deng1
1School of Pharmacy and Pharmaceutical Sciences, The University of Queensland, Brisbane, Australia.
Introduction:
Population-level models predicting tobacco use would benefit from inclusion of an accurate anabasine excretion factor. This study aimed to explore the excretion of anabasine in people who use conventional cigarettes (CCs) and nicotine vaping products (NVPs).
Methods:
A total of 72 participants were enrolled: 22 people who smoked CCs, 20 people who used NVPs, and 30 people who had never smoked or vaped. The quantity of CC and NVP use was documented over a 3-day period. Composite 24-hour urine samples were collected on Day 3 and analysed using LC-MS/MS to quantify nicotine, cotinine (COT), 3-hydroxycotinine (3HC), anabasine and anatabine. The anabasine excretion factor was calculated for urine samples containing anabasine.
Results:
Nicotine exposure, as the molar sum of nicotine and its metabolites (COT and 3HC) was higher for the NVP group compared to the CC group (p = 0.0460). Anabasine concentrations were low in urine of the NVP group but the difference from the CC group did not reach statistical significance (p = 0.0646). Data from 19 individuals in the CC group was used to calculate anabasine excretion factor, giving a value of 9.02%.
Conclusions:
The excretion factor for anabasine was calculated from 24-hour urine samples for 19 individuals who smoked cigarettes, providing a preliminary estimate that may be incorporated into predictive modelling for population-level tobacco product use. Given the small sample size of this study, future research with larger cohorts is required to provide more reliable estimates.
さらに関連する動画
09:50Impact Assessment of Repeated Exposure of Organotypic 3D Bronchial and Nasal Tissue Culture Models to Whole Cigarette Smoke
Published on: February 12, 2015
10:44Comparing the Effects of Electronic Cigarette Vapor and Cigarette Smoke in a Novel In Vivo Exposure System
Published on: May 24, 2017
関連する概念動画
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
Toxicity Testing in Animals
Drug Excretion: Pulmonary and Glandular Routes
Drugs can also be excreted in breast milk, which is crucial for breastfeeding infants. The...
Statistical Methods for Analyzing Epidemiological Data
